Dec 9, 2024Journal ArticleTherapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial Disparities.Written by 2 Roon authors & 8 others Via Annals of Surgical Oncology
ResearchA Phase I/II Study of Preoperative Letrozole, Everolimus, and Carotuximab in Stage 2 and 3 Hormone Receptor-Positive and Her2-Negative Breast Cancer
ResearchMutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma
ResearchOperational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model
ResearchOpen-label, Phase II, Multicenter Study of Lasofoxifene plus Abemaciclib for Treating Women with Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation after Disease Progression on Prior Therapies: ELAINE 2
ResearchDetection of Microsatellite Instability High (MSI-H) Status by Targeted Plasma-Based Genotyping in Metastatic Breast Cancer
ResearchEffect of Prior Treatments on Post-CDK 4/6 Inhibitor Survival in Hormone Receptor-Positive Breast Cancer
ResearchGenetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
ResearchNCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020